11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome. 115-. (canceled)17. The method of claim 16 , wherein Ris -1 claim 16 ,4-cyclohexyl-Ror —CH-1 claim 16 ,4-cyclohexyl-R.18. The method of claim 17 , wherein Ris C(O)R.19. The method of claim 18 , wherein Ris hydroxy.20. The method of claim 17 , wherein Ris selected from —CH—O-aryl claim 17 , —CH—O-hetaryl claim 17 , —O-aryl claim 17 , —O-hetaryl claim 17 , —CH—O—Calkyl claim 17 , or —NHC(O)R claim 17 , wherein the aryl claim 17 , hetaryl claim 17 , and alkyl groups are each optionally substituted with one or more R.21. The method of claim 17 , wherein Ris —NH—S(O)-aryl claim 17 , —NH—S(O)-hetaryl claim 17 , —NH-aryl claim 17 , —NH-hetaryl claim 17 , —S(O)-aryl claim 17 , or —S(O)-hetaryl claim 17 , where the aryl and hetaryl groups are each optionally substituted with one or more R.22. The method of claim 16 , wherein Ris -4-piperidin-1-yl-R claim 16 , or —CH-4-piperidin-1-yl-R.23. A method of lowering intracellular glucocorticoid levels in a subject claim 16 , the method comprising administering to a subject a compound claim 16 , which is a compound selected from the group consisting of:4-(1-Cyclopropanecarbonyl-piperidin-4-yloxy)-N-adamantan-2-yl-benzamide;4-[1-(3-Methyl-butyryl)-piperidin-4-yloxy]-N-adamantan-2-yl-benzamide;4-[4-(Cyclopropanecarbonyl-amino)-cyclohexyloxy]-N-adamantan-1-yl-benzamide;4-[4-(Cyclopropane-carbonyl-amino)-cyclo-hexyloxy]-N-adamantan-2-yl-benzamide;N-Adamantan-2-yl-4-(4-hydroxy-cyclohexyloxy)-benzamide;4-[4-adamantan-2-ylcarbamoyl)-phenoxy]-cyclohexanecarboxylic acid;N-Adamantan-2-yl-4-[4-(4-methyl-1H-imidazol-2- ...

11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds

The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Growth Hormones with Prolonged In-Vivo Efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. 1. A growth hormone conjugate which comprises a growth hormone compound (GH) linked to an albumin binding residue via a hydrophilic spacer , or a pharmaceutically acceptable salt , solvate or prodrug thereof.2. The conjugate of wherein the growth hormone conjugate has the formula (I):{'br': None, 'A-W-B-GH \u2003\u2003(I)'}wherein:GH is a growth hormone compound,B is a hydrophilic spacer,W is a chemical group linking A and B, andA is an albumin binding residue;3. The conjugate of claim 1 , wherein GH is hGH (SEQ ID NO:1).6. The conjugate of claim 4 , whereinI1, I2, I3, I4, I5 and I6 independently are 0-6,m1, m3, m4, m6 and m7 independently are 0-6,m2 and m5 independently are 0-10, andn1, n2, n3 and n4 independently are 0-10.7. The conjugate of claim 4 , wherein D1 and D2 are independently selected from —O— or —NR— or a valence bond.8. The conjugate of claim 4 , wherein E1 and E2 are independently selected from —O— or —NR— or a valence bond.9. The conjugate of claim 4 , wherein Wthrough Windependently are selected from the group consisting of —C(O)NH— claim 4 , —NHC(O)— claim 4 , —C(O)NHCH— claim 4 , —CHNHC(O)— claim 4 , —C(O)NHS(O)— claim 4 , —S(O)NHC(O)— and a valence bond.10. The conjugate of claim 4 , wherein R claim 4 , R claim 4 , R claim 4 , Rand Rindependently are selected from the group consisting of hydrogen claim 4 , —C(O)OH claim 4 , —C(O)NH claim 4 , —S(O)OH and C-alkyl claim 4 , wherein the alkyl group optionally is substituted with —C(O)OH claim 4 , —C(O)NH claim 4 , or —S(O)OH.12. The conjugate of claim 1 , wherein the albumin binding residue via a hydrophilic spacer is attached to the glutamine residue in the position corresponding to position 40 in SEQ ID No. 1 claim 1 , or the glutamine residue in the position corresponding to position 141 in SEQ ID No. 1 ...

Growth Hormones With Prolonged In-Vivo Efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy. 1. A growth hormone conjugate which comprises a growth hormone compound (GH) havinga) a single Cys mutation,b) an additional disulfide bridge, orc) a single Cys mutation and an additional disulfide bridge,wherein an albumin binding residue via a hydrophilic spacer is linked to said GH, or a pharmaceutically acceptable salt thereof.3. The conjugate of wherein the hydrophilic spacer is linked toa) the N-terminal or Gln40 or Gln141 of the growth hormone compound orb) the sulphur residue of a single Cys mutation present in the growth hormone compound selected from the group consisting of; T3C, P5C, S7C, D11C, H18C, Q29C, E30C, E33C, A34C, Y35C, K38C, E39C, Y42C, S43C, D47C, P48C, S55C, S57C, P59C, S62, E65C, Q69C, E88C, Q91C, S95C, A98C, N99C, S100C, L101C, V102C, Y103C, D107C, S108C, D112C, Q122C, G126C, E129C, D130C, G131C, P133C, T135C, G136C, T142C, D147C, N149C, D154C, A155C, L156C, R178C, E186C, G187C and G190C SEQ ID NO: 1.4. The conjugate of claim 1 , wherein the GH has an additional disulfide bridge between at least one of the amino acid pairs in the positions selected from the group consisting of R16C/L117C claim 1 , A17C/E174C claim 1 , H21C/M170C claim 1 , D26C/V102C claim 1 , D26C/Y103C claim 1 , N47C/T50C claim 1 , Q49C/G161C claim 1 , F54C/Y143C claim 1 , F54C/S144C claim 1 , F54C/F146C claim 1 , S55C/Y143C claim 1 , S57C/Y143C claim 1 , I58C/Q141C claim 1 , I58C/Y143C claim 1 , I58C/S144C claim 1 , P59C/Q137C claim 1 , P61C/E66C claim 1 , P61C/T67C claim 1 , S71C/S132C claim 1 , L73C/S132C claim 1 , L73C/F139C claim 1 , R77C/I138C claim 1 , R77C/F139C claim 1 , L81C/Q141C claim 1 , L81C/Y143C ...

METHOD FOR IMPLEMENTING BOOTSTRAP-SUPPLY CHARGING IN A MOTOR CONTROLLER AT ENERGIZED MOTOR AND MOTOR CONTROLLER USING SUCH A METHOD

The present invention relates to a motor controller employing bootstrap-capacitor supplies and in particular to the situation where the bootstrap supplies have to be charged, while the motor controller is connected to a spinning and energized motor. The present invention introduces a method of recharging based on choosing a recharging sequence from a set of recharging sequences, where the choice depends on the state of the connected motor and in particular on the back-EMF voltages of the motor. 114-. (canceled)15. A method of recharging a controller with inoperative switching elements comprising a bootstrap capacitor and having at least two output phases , the controller being connected to a load generating back-EMFs at the output terminals of the controller , wherein the load is a motor and the controller is a motor controller , the method comprising a recharge sequence for the bootstrap capacitor of each output phase , and selecting each recharge sequence from a set of at least two recharge sequences in relation to or as a function of the back-EMFs of the load , where the choice is based on the spinning of the load in relation to a base frequency , or alternatively the amplitude of the back-EMFs in relation to a base amplitude of the back-EMFs.16. The method according to claim 15 , wherein the recharging sequences are bootstrap-charging processes.17. The method according to claim 15 , wherein the back-EMF is caused by a spinning motor.18. The method according to claim 15 , wherein the motor is a three-phase motor claim 15 , the motor controller thus being a three-phase motor controller.19. The method according to claim 15 , wherein the set of recharging sequences comprises a high-frequency zone claim 15 , defined as when the motor spins above an upper threshold level.20. The method according to claim 19 , wherein the set of recharging sequences comprises a low-frequency zone claim 19 , defined as when the motor spins below a lower threshold level claim 19 , the ...

SULFONATED POLY(ARYLENES), POLYMER COMPOUNDS AND METHODS OF PRODUCING THE SAME

A copolymer containing, in addition to recurring elements of a sulfonated poly(arylene) containing exclusively recurring structural element(s) of the general formulas —[—Ar(SOM)-X—]— and —[—Ar(SOM)-Y—]—, wherein X and Y, which are identical or different from each other, each represent an electron-acceptor group, Arand Ar, which are either identical or different from each other, represent an aromatic or heteroaromatic ring system with 5-18 ring atoms; wherein the aromatic or heteroaromatic ring system, in addition to the SOM and the substituents X and Y, optionally comprises additional substituents which are not electron-donor groups; M represents monovalent cation and n is an integral number between 1 and 4; and wherein X, Y, Ar, Ar, M and n can be identical or different in various structural elements, independently of each other, one or several additional elements of at least one additional monomer or macromonomer. 1. A copolymer containing , in addition to recurring elements of a sulfonated poly(arylene) containing exclusively recurring structural element(s) of the general formulas —[—Ar(SOM)-X—]— and —[—Ar(SOM)-Y—]— , wherein X and Y , which are identical or different from each other , each represent an electron-acceptor group , Arand Ar , which are either identical or different from each other , represent an aromatic or heteroaromatic ring system with 5-18 ring atoms; wherein the aromatic or heteroaromatic ring system , in addition to the SOM and the substituents X and Y , optionally comprises additional substituents which are not electron-donor groups; M represents monovalent cation and n is an integral number between 1 and 4; and wherein X , Y , Ar , Ar , M and n can be identical or different in various structural elements , independently of each other , one or several additional elements of at least one additional monomer or macromonomer.2. The copolymer according to claim 1 , wherein the (at least) one additional monomer or macromonomer is a α claim 1 ,ω- ...

GROWTH HORMONE CONJUGATES

The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant. 1. A growth hormone conjugate of formula (I){'br': None, 'A-W—B-GH\u2003\u2003(I)'}whereinGH represents a growth hormone compound,A represents a bile acid residue,B represents a hydrophilic spacer covalently linked to GH,W is a chemical group linking A and B;and a pharmaceutically acceptable salt.2. The growth hormone conjugate according to claim 1 , wherein the growth hormone compound GH comprises one or more additional disulfide bond(s) compared to human growth hormone (hGH) as defined by SEQ ID NO 1.3. The growth hormone conjugate according to claim 2 , wherein the growth hormone compound comprises one or more additional disulfide bond(s) connecting a loop segment and a helical segment.4. The growth hormone conjugate according to claim 1 , wherein the compound comprise at least one pair of mutations corresponding to R16C/L117C claim 1 , A17C/E174C claim 1 , H21C/M170C claim 1 , D26N102C claim 1 , D26/Y103C claim 1 , N47C/T50C claim 1 , Q49C/G161C claim 1 , F54C/Y143C claim 1 , F54C/S144C claim 1 , F54C/F146C claim 1 , S55C/Y143C claim 1 , S57C/Y143C claim 1 , 158C/Q141C claim 1 , 158C/Y143C claim 1 , 158C/S144C claim 1 , P59C/Q137C claim 1 , P61C/E66C claim 1 , P61C/T67C claim 1 , S71C/S132C claim 1 , L73C/S132C claim 1 , L73C/F139C claim 1 , R77C/1138C claim 1 , R77C/F139C claim 1 , L81C/Q141C claim 1 , L81C/Y143C claim 1 , Q84C/Y143C claim 1 , Q84C/S144C claim 1 , S85C/Y143C claim 1 , S85C/S144C claim 1 , P89C/F146C claim 1 , F92C/F146C claim 1 , F92C/T148C claim 1 , R94C/D107C claim 1 , V102C/A105C claim 1 , L156C/F146C claim 1 , L156C/T148C and/or V185C/S188C in SEQ ID NO 1.5. The growth hormone compound according to claim 2 , wherein the growth hormone compound comprises one or more additional disulfide bond(s) ...

ANTAGONISTIC DR3 LIGANDS

The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DRligands useful for treating inflammatory diseases. 1. A monovalent antagonistic DR3 antibody , wherein said monovalent antibody blocks binding of DR3 to TL1A , and wherein said monovalent antibody in a bivalent form thereof is an agonistic antibody that blocks binding of DR3 to TL1A.2. A monovalent antibody according to claim 1 , wherein the monovalent antibody is not an antibody having the CDR sequences of the 11H08 antibody set forth in WO2011106707 (SEQ ID NOs 14+15).3. A monovalent antibody according to claim 1 , wherein said monovalent antibody is conjugated with a lipophilic moiety.4. A monovalent antibody according to claim 3 , wherein said lipophilic moiety comprises a —(CH)—CO— fatty acyl group claim 3 , wherein n is 16-18.5. A monovalent antibody according to claim 3 , wherein said lipophilic moiety comprising a —(CH)—CO— fatty acyl group claim 3 , wherein n is 15.7. A monovalent antibody according to claim 3 , wherein said lipophilic moiety is attached to a naturally occurring C239 (Kabat numbering) cysteine residue in the heavy chain of the antibody via a hydrophilic spacer.8. A monovalent antibody according to claim 1 , wherein said antibody binds to an epitope on DR3 claim 1 , wherein said epitope comprises I43 and/or L45 of SEQ ID NO 1.9. A monovalent antibody according to claim 1 , wherein said antibody binds an epitope on DR3 claim 1 , wherein said epitope comprises at least one of amino acids G37 to L45 and at least one of amino acids L57 to A59 as set forth in SEQ ID NO 1.10. A monovalent antibody according to claim 9 , wherein said epitope comprises amino acids G37 to L45 and amino acids L57 to A59 as set forth in SEQ ID NO 1.11. A monovalent antibody according to claim 1 , wherein said ligand is a Fab fragment.12. A monovalent antibody according to claim 1 , wherein said monovalent antibody binds DR3 with a ...

ANTAGONISTIC DR3 LIGANDS

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. 1. An isolated monovalent antagonistic DR3 antibody , the antibody comprising a heavy chain comprising a heavy chain CDR1 , a heavy chain CDR2 , and a heavy chain CDR3 and a light chain comprising a light chain CDR1 , a light chain CDR2 , and a light chain CDR3 , the heavy chain CDR1 comprising an amino acid sequence corresponding to Kabat residues 31-35B of SEQ ID NO:10; the heavy chain CDR2 comprising an amino acid sequence corresponding to Kabat residues 50-58 of SEQ ID NO:10; the heavy chain CDR3 comprising an amino acid sequence corresponding to Kabat residues 95-102 of SEQ ID NO:10; the light chain CDR1 comprising an amino acid sequence corresponding to Kabat residues 24-34 of SEQ ID NO:11; the light chain CDR2 comprising an amino acid sequence corresponding to Kabat residues 50-56 of SEQ ID NO:11; and the light chain CDR3 comprising an amino acid sequence corresponding to Kabat residues 89-97 of SEQ ID NO:11.2. The isolated monovalent antagonistic DR3 antibody of claim 1 , wherein the heavy chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:10 claim 1 , and wherein the light chain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:11.3. The isolated monovalent antagonistic DR3 antibody of claim 2 , wherein the heavy chain comprises an amino acid sequence of SEQ ID NO:10 claim 2 , and wherein the light chain comprises an amino acid sequence of SEQ ID NO:11.4. The isolated monovalent antagonistic DR3 antibody of claim 1 , wherein the monovalent antibody is conjugated with a lipophilic moiety.5. The isolated monovalent antagonistic DR3 antibody of claim 4 , wherein the lipophilic moiety comprises a —(CH)—CO— fatty acyl group claim 4 , and wherein n is 16-18.6. The isolated monovalent antagonistic DR3 antibody of claim 4 , ...

APPARATUS, METHOD, SYSTEM AND SOFTWARE PRODUCT FOR HAND SANITISATION

An apparatus and method for hand sanitisation by application of ozone. The apparatus includes a disinfecting chamber having at least one port for receiving a hand therein and a sensor for detecting entry or exit of the hand into the chamber. The apparatus delivers ozone water to the hand while a controller provides start and stop times for the delivery of the ozone water. This results in improved sanitisation of the hand or hands. 1111325ab. An apparatus ( , , ,) for hand sanitisation by application of ozone , the apparatus comprising ,{'b': 3', '3', '110, 'claim-text': [{'b': 2', '3', '110, 'at least one port () adapted for insertion of at least one hand into the disinfecting chamber (, ),'}, {'b': 4', '26', '3', '110, 'at least one sensor () adapted for detection of an entry and/or exit of the at least one hand () into the disinfecting chamber (, ),'}, {'b': 7', '130', '8', '18', '26', '3', '3', '110, 'at least one ozone water output (,) of an ozone water supply () that comprises an electrolytic ozone generator () and being arranged to deliver ozone water to the at least one hand () when inserted into the disinfecting chamber (,′, ),'}, {'b': '6', 'claim-text': [{'b': 7', '130', '3', '3', '110', '4', '26', '3', '3', '110, 'is arranged to start a discharge of ozone water from the at least one ozone water output (,) into the disinfecting chamber (,′, ) when the at least one sensor () detects entry of the at least one hand () into the disinfecting chamber (,′, ),'}, {'b': 7', '130', '6, 'is arranged to stop the discharge of ozone water from the at least one ozone water output (,) in response to an input from the control means (),'}, {'b': 5', '4', '26', '3', '110, 'comprises a timer () arranged to cooperate with the at least one sensor () to regulate a sanitisation timing of the at least one hand () inserted in the disinfecting chamber (, ),'}], 'a control means () which'}], 'a disinfecting chamber (,′, ) having'}wherein{'b': 7', '130', '3', '110', '33', '26', '34', ...

TWO-DIMENSIONAL AMORPHOUS CARBON COATING AND METHODS OF GROWING AND DIFFERENTIATING STEM CELLS

Described is a composite material composed of an atomically thin (single layer) amorphous carbon disposed on top of a substrate (metal, glass, oxides) and methods of growing and differentiating stem cells. 16-. (canceled)8. The method of claim 7 , comprising:heating the substrate to a temperature of ≤500° C. prior to the forming.9. The method of claim 7 , wherein the 2D amorphous carbon film is formed as a continuous film over substantially the entire substrate surface.10. The method of claim 7 , comprising:separating the 2D amorphous carbon film from the surface of the substrate to obtain a free-standing 2D amorphous carbon film.11. The method of claim 7 , comprising:transferring a free-standing 2D amorphous carbon film onto a surface of another substrate.1220-. (canceled) This application claims benefit of priority of U.S. Provisional Patent Application No. 62/463,112 entitled, “LAYERED COMPOSITE MATERIAL CONSISTING ATOMICALLY THIN AMORPHOUS CARBON ON TOP OF THE SUBSTRATE,” filed Feb. 24, 2017, and U.S. Provisional Patent Application No. 62/546,680 entitled, “THERAPEUTIC COATING AND METHODS OF GROWING AND DIFFERENTIATING STEM CELLS,” filed Aug. 17, 2017. The entire contents and disclosures of these patent applications are incorporated herein by reference in their entirety.The present disclosure relates to generally to two-dimensional amorphous carbon (2DAC) coating and articles and methods of growing and differentiating stem cells.A need exists within the prior art to develop and provide suitable applications for a coating intended for specific purposes such as biomedical applications.According to first broad aspect, the present disclosure provides a two-dimensional (2D) amorphous carbon film, wherein the 2D amorphous carbon film has a crystallinity (C)≤0.8.According to a second broad aspect, the present disclosure provides a two-dimensional (2D) amorphous carbon film, wherein the 2D amorphous carbon film has a crystallinity (C)<1 and a sp/spbond ratio is 0.2 or ...

Growth Hormones with Prolonged In-Vivo Efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy. This application is a continuation of U.S. application Ser. No. 13/522,390, filed Jul. 16, 2012, which is a 35 U.S.C. §371 national stage application of International Patent Application PCT/EP2011/050923 (published as WO2011/089255), filed Jan. 24, 2011, which claims priority of European Patent Application 10151405.7, filed Jan. 22, 2010; this application further claims priority under 35 U.S.C. §119 of U.S. Provisional Application 61/297,305, filed Jan. 22, 2010, all of which are hereby incorporated by reference.The present invention relates to a growth hormone compound linked to an albumin binding residue via a hydrophilic spacer, and to methods of preparing and using such compounds. These growth hormone conjugates have increased resistance to proteolytic degradation in combination with a protracted profile of action and are useful in therapy.In accordance with 37 C.F.R. §1.52(e)(5), Applicants enclose herewith the Sequence Listing for the above-captioned application entitled “SEQUENCE LISTING”, created on Jul. 10, 2012. The Sequence Listing is made up of 2,026 bytes, and the information contained in the attached “SEQUENCE LISTING” is identical to the information in the specification as originally filed. No new matter is added.Growth hormone is a polypeptide hormone secreted by the anterior pituitary in mammals. Dependent on species growth hormone is a protein composed of approximately 190 amino acid residues corresponding to a molecular weight of approximately 22 kDa. Growth hormone binds to and signals through cell surface receptors, the growth hormone receptors (GHR). Growth hormone plays a key role ...

METHOD FOR DETERMINING RECTIFIER-STAGE OUTPUT CURRENT AND/OR GRID-SIDE CURRENTS OF A FREQUENCY CONVERTER

A method for determining rectifier-stage output current and/or grid-side currents (iu, iv, iw) of a frequency converter () having a passive rectifier (), an inverter (), a DC-link with a DC-link inductor (Ldc) and a DC-link capacitor (Cdc) between the rectification stage () and the inverter stage () is described. In a frequency converter the current information for the grid-side currents (iu, iv, iw) should be obtained without a current sensor at the grid-side (). To this end the method comprises the step of calculating a current in the DC-link () by using at least a voltage value (Urec) and characteristics of the rectifier () in the DC-link () and/or grid side currents to form a corrected current using the calculated current and a measured current or currents or a fraction of a measured current or currents, or a fraction of a measured current or currents. 1. A method for determining rectifier-stage output current and/or grid-side currents of a frequency converter having a passive rectifier , an inverter , a DC-link with a DC-link inductor and a DC-link capacitor between the rectifier and the inverter and/or an AC-inductor at the grid side of the rectification stage , wherein the method comprises the step of calculating a current in the DC-link and/or grid side currents by using at least a voltage value and characteristics of the rectification stage and/or the DC-link to form a corrected current using the calculated current and a measured current or currents , or a fraction of a measured current or currents.2. The method according to claim 1 , wherein the calculated current and/or the absolute value of the calculated grid-side currents each contains an AC component and a DC component claim 1 , where each corrected current is determined by separating the calculated AC and DC components and then adjusting the calculated DC component by a measured current or a fraction of a measured current from the inverter side of the frequency converter.3. The method according to ...

BONE IMPLANT

The present invention relates to a bone implant device, comprising a body having a first part and an opposite second part, the first part and an opposite second part defining a longitudinal axis, the first part including an external thread extending from a cylindrical part to the distal end of the body, the external thread comprising a first thread part having a first radius measured from the longitudinal axis and a second thread part having a second radius measured from the longitudinal axis. The first radius is larger than the second radius, the first thread part is a cutting part, and the second thread part is a contact surface. The first part may include one or more cavities for storing bone fragments while the bone implant is in use. 1. A bone implant device comprising:a body having a first part and an opposite second part, the first part and an opposite second part defining a longitudinal axis,the first part including an external thread extending from a cylindrical part to the distal end of the body,the external thread comprising a first thread part having a first radius measured from the longitudinal axis and a second thread part having a second radius measured from the longitudinal axis, and the first radius is larger than the second radius, wherein the first thread part is a cutting part and the second thread part is a contact surface, the first part including one or more cavities for storing bone fragments while the bone implant is in use.2. The bone implant device according to claim 1 , wherein a transition part is formed between the first thread part and the second thread part and the transition part defines a smooth transition.3. The bone implant device according to wherein a transition part is formed between the first thread part and the second thread part and the transition part defines a discontinuous transition.4. The bone implant device according to claim 1 , further comprising one or more cavities at the first part of the bone implant device.5. ...

TWO DIMENSIONAL AMORPHOUS CARBON AS OVERCOAT FOR HEAT ASSISTED MAGNETIC RECORDING MEDIA

A recording device comprising an overcoat layer, wherein the overcoat layer comprises an amorphous carbon overcoat layer having a crystallinity (C)≤0.8. 1. A recording device comprising:an overcoat layer on a substrate,wherein the overcoat layer comprises an amorphous carbon layer having a crystallinity (C)≤0.8.2. The device of claim 1 , wherein the overcoat layer comprises a two-dimensional (2D) amorphous carbon film.3. The device of claim 2 , wherein the 2D amorphous carbon film has a resistivity of 0.01 to 1000 Ω-cm claim 2 , inclusive.4. The device of claim 2 , wherein the 2D amorphous carbon film has a crystallinity (C)<1 and a sp/spbond ratio is 0.2 or less.5. The device of claim 2 , wherein the 2D amorphous carbon film has a transparency equal to or greater than 98% at a wavelength of 550 nm or higher.6. The device of claim 2 , wherein a water contact angle of the overcoat layer is 60.7. The device of claim 2 , wherein the 2D amorphous carbon film contains an Sp2 carbon bond of more than 99%.8. The device of claim 2 , wherein the 2D amorphous carbon film is stable up to 700° C.9. The device of claim 2 , wherein a friction range of the 2D amorphous carbon film is approximately 0.2-0.4.10. The device of claim 2 , wherein the 2D amorphous carbon film has a reflection less than 5% in an ultraviolet (UV) region.11. The device of claim 1 , wherein the recording device comprises a magnetic recording media.12. The device of claim 13 , wherein the recording device is a heat assisted magnetic recording media.13. The device of claim 1 , comprising:an underlying magnetic recording layer,wherein the overcoat layer protects the underlying magnetic recording layer.14. The device of claim 1 , comprising additional layers.15. The device of claim 14 , wherein the additional layers are selected from the group consisting of:a substrate layer;an adhesion layer;a heat sink layer;a soft under layer;another under layer;a recording layer;a capping layer; a lubricant layer; and ...

AMMONIA CRACKING

A process for generating power using a gas turbine, comprising the steps of: (i) vaporising and pre-heating liquid ammonia to produce pre-heated ammonia gas; (ii) introducing the pre-heated ammonia gas into an ammonia-cracking device suitable for converting ammonia gas into a mixture of hydrogen and nitrogen; (iii) converting the pre-heated ammonia gas into a mixture of hydrogen and nitrogen in the device; (iv) cooling the mixture of hydrogen and nitrogen to give a cooled hydrogen and nitrogen mixture; (v) introducing the cooled hydrogen and nitrogen mixture into a gas turbine; and (vi) combusting the cooled hydrogen and nitrogen mixture in the gas turbine to generate power. 1. A process for generating power using a gas turbine , comprising the steps of:(i) vaporising and pre-heating liquid ammonia to produce pre-heated ammonia gas;(ii) introducing said pre-heated ammonia gas into an ammonia-cracking device, wherein said device is suitable for converting ammonia gas into a mixture of hydrogen and nitrogen;(iii) converting said pre-heated ammonia gas into a mixture of hydrogen and nitrogen in said device;(iv) cooling said mixture of hydrogen and nitrogen to give a cooled hydrogen and nitrogen mixture;(v) introducing said cooled hydrogen and nitrogen mixture into a gas turbine; and(vi) combusting said cooled hydrogen and nitrogen mixture in said gas turbine to generate said power.2. A process as claimed in claim 1 , wherein a fuel source assists the conversion of said pre-heated ammonia gas into said mixture of hydrogen and nitrogen in said ammonia-cracking device claim 1 , optionallywherein said fuel source comprises a portion of said cooled hydrogen and nitrogen mixture, preferablywherein said fuel source comprises 10-20% of said cooled hydrogen and nitrogen mixture.3. (canceled)4. (canceled)5. A process as claimed in claim 1 , wherein said vaporising and pre-heating of said liquid ammonia occurs at a temperature of 300-700° C. and/or at a pressure of 2-50 barg.6. ( ...

Growth Hormones with Prolonged In-Vivo Efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy. 3. The conjugate of wherein the hydrophilic spacer is linked toa) the N-terminal or Gln40 or Gln141 of the growth hormone compound orb) the sulphur residue of a single Cys mutation present in the growth hormone compound selected from the group consisting of T3C, PSC, S7C, D11C, H18C, Q29C, E30C, E33C, A34C, Y35C, K38C, E39C, Y42C, S43C, D47C, P48C, S55C, S57C, P59C, S62, E65C, Q69C, E88C, Q91C, S95C, A98C, N99C, S100C, L101C, V102C, Y103C, D107C, S108C, D112C, Q122C, G126C, E129C, D130C, G131C, P133C, T135C, G136C, T142C, D147C, N149C, D154C, A155C, L156C, R178C, E186C, G187C and G190C of SEQ ID NO: 1.4. The conjugate of claim 1 , wherein the GH has an additional disulfide bridge between at least one of the amino acid pairs in the positions selected from the group consisting of R16C/L117C claim 1 , A17C/E174C claim 1 , H21C/M170C claim 1 , D26C/V102C claim 1 , D26C/Y103C claim 1 , N47C/T50C claim 1 , Q49C/G161C claim 1 , F54C/Y143C claim 1 , F54C/S144C claim 1 , F54C/F146C claim 1 , S55C/Y143C claim 1 , S57C/Y143C claim 1 , I58C/Q141C claim 1 , I58C/Y143C claim 1 , I58C/S144C claim 1 , P59C/Q137C claim 1 , P61C/E66C claim 1 , P61C/T67C claim 1 , S71C/S132C claim 1 , L73C/S132C claim 1 , L73C/F139C claim 1 , R77C/I138C claim 1 , R77C/F139C claim 1 , L81C/Q141C claim 1 , L81C/Y143C claim 1 , Q84C/Y143C claim 1 , Q84C/S144C claim 1 , S85C/Y143C claim 1 , S85C/S144C claim 1 , P89C/F146C claim 1 , F92C/F146C claim 1 , F92C/T148C claim 1 , R94C/D107C claim 1 , V102C/A105C claim 1 , L156C/F146C claim 1 , L156C/T148C and V185C/S188C in SEQ ID NO: 1.8. The conjugate of claim 7 , wherein D1 and D2 are independently ...

PRODUCT CONFIGURATION

A valid configuration of a product is determined by a computer based on a complete product model. The initial product model includes variables with associated values, and rules, wherein the variables and rules define a configuration problem to be solved. Some variables of the initial product model are defined as scope variables. Based on the selected values for scope variables the initial product model is restricted by the computer to a simplified product model. The simplified product model is employed in order to set the values of the variables not being defined as scope variables in an iterative computer-implemented process. 2. The method of claim 1 , further comprising:generating Rule Binary Decision Diagrams, R-BDDs, representing the rules of the initial product model,restricting the R-BDDs based on the set value from the set of values of the at least one scope variable resulting in Scope Restricted Rule Binary Decision Diagrams, SRR-BDDs, representing the rules of the remaining simplified product model.3. The method of claim 1 , further comprising generating a Tree of Binary Decision Diagrams claim 1 , ToBDDs claim 1 , representing the simplified product model claim 1 , wherein the iterative setting of values for other variables not being scope variables is based on the ToBDDs.4. The method of claim 1 , further comprising:generating R-BDDs representing the rules of the initial product model,a restricting the R-BDDs based on the set value from the set of values of the at least one scope variable resulting in SRR-BDDs representing the rules of the remaining simplified product model,generating a ToBDDs representing the simplified product model, wherein the iterative setting of values for other variables not being scope variables is based on the ToBDDs.5. The method of claim 1 , wherein at least two variables are defined as scope variables claim 1 , the method further comprising:generating a Scope Binary Decision Diagram, S-BDD, representing those combinations ...

PULSE SHIFT PROTECTION METHOD FOR DETECTING A PHASE-TO-PHASE SHORT CIRCUIT IN A DRIVE AND A DRIVE FOR EXECUTING THE METHOD

The present invention is directed at a pulse shift protection method for detecting a phase-to-phase short circuit in a drive for controlling electric motors, wherein the drive provides an output voltage to the electric motor, and wherein the instant, at which a short circuit detection function is executed, is chosen to minimize disturbance in the output voltage of the drive. The invention is also directed at a drive for controlling electric motors, said drive including a controlling portion for generating an output signal and an output portion connectable to an electric motor. The drive is provided for executing the above-mentioned pulse shift protection method. 1. A pulse shift protection method for detecting a phase-to-phase short circuit in a drive for controlling electric motors , wherein the drive provides an output voltage to the electric motor and wherein the instant , at which a short circuit detection function is executed , is chosen to minimize disturbance in the output voltage of the drive , wherein the short circuit detection function is executed at instances , which are calculated online.2. The pulse shift protection method according to claim 1 , wherein the online calculated instances at which to perform the short circuit detection function are calculated so that the output voltage of the drive is as far as possible form active vectors of the drive.3. The pulse shift protection method according to claim 1 , wherein the short circuit detection function is executed at instances claim 1 , which are determined based on a timer and the instant of the latest execution of the short circuit detection function.4. The pulse shift protection method according to claim 3 , wherein the timer is reset at every execution of the short circuit detection function.5. The pulse shift protection method according to claim 1 , wherein the execution of the short circuit detection function is delayed or advanced in order to maintain a minimum distance between the execution of ...

The combination of a physical model of a set of a patient's teeth and an elongated implant analog, an elongated implant analog and a method of making a physical model of a set of teeth

The invention relates to a physical model of a person's teeth and to an analog configured to mutually snap engage upon insertion of the analog to a the desired depth into a hole in the physical model representative of an implant in the person's bone, with a peripheral or annular space between the analog and the model in the hole between the location of the snap engagement and a distal portion that together with the snap engagement define contact areas serving to keep the analog from sideways or turning movements within the hole.

HUMAN-MACHINE INTERFACE WITH GRAPHENE-PYROELECTRIC MATERIALS

A version of the invention comprises a device for controlling or interfacing with a computer or other form of communicable machine based on the pyroelectric effect, and includes at least one optically- and infrared- (IR-) transparent graphene electrode. 1. A control device for interfacing between a human and a communicable machine based on the pyroelectric effect , the control device comprising:at least one graphene electrode configured to transmit at least a portion of infrared radiation, emitted from the at least a portion of the human's body in a motion relative to the control device, to at least one pyroelectric active layer;the at least one pyroelectric active layer, said at least one pyroelectric active layer being configured to undergo a reorientation of dipoles in response to the portion of the infrared radiation received through the at least one graphene electrode; andat least one rear electrode;the at least one graphene electrode, the at least one pyroelectric active layer and the at least one rear electrode defining at least one pixel configured to generate an electrical signal, in response to the motion of the at least a portion of the human's body relative to the control device, based on at least the reorientation of the dipoles in the at least one pyroelectric active layer.2. The control device of claim 1 , wherein the at least one pyroelectric active layer is optically transparent or wherein the at least one pyroelectric active layer is optically opaque.3. The control device of claim 2 , wherein the at least one pyroelectric active layer comprises polyvinylidene fluoride or a co-polymer of polyvinylidene fluoride.4. The control device of claim 3 , wherein the at least one pyroelectric active layer comprises polyvinylidene fluoride-co-trifluoroethylene.5. (canceled)6. The control device of Claim 2 , wherein the at least one pyroelectric active layer comprises lead zirconate titanate.7. The control device of claim 1 , wherein the at least one rear ...

POWER ELECTRONIC DEVICE

A power electronic device () is described comprising an input which is connected to an over-current-protection device arrangement () and a DC-link (), wherein the DC-link () comprises a series connection of at least two DC-link capacitors (Cdc). In such a power electronic device the risk of a fire hazard should be minimized. To this end fault detecting means () are provided detecting an imbalance between the DC-link capacitors (Cdc) or an overload of at least one of the DC-link capacitors (Cdc), wherein the fault detecting means () control maximum current inducing means connected to the DC-link. 1. A power electronic device comprising an input which is connected to an over-current-protection device arrangement and a DC-link , wherein the DC-link comprises a series connection of at least two DC-link capacitors (Cdc) , wherein fault detecting means are provided detecting an imbalance between the DC-link capacitors (Cdc) or an overload of at least one of the DC-link capacitors (Cdc) , wherein the imbalance detecting means control maximum current inducing means connected to the DC-link.2. The power electronic device according to claim 1 , wherein the fault detecting means detect at least one parameter of at least one of the DC-link capacitors (Cdc).3. The power electronic device according to claim 2 , wherein the fault detecting means compare at least a parameter of one of the capacitors (Cdc) with a parameter of another one of the capacitors (Cdc).4. The power electronic device according to claim 3 , wherein the parameter is a voltage over the capacitor (Cdc) a current through the capacitor (Cdc) claim 3 , or a temperature of the capacitor (Cdc).5. The power electronic device according to claim 1 , wherein an inverter is connected to the DC-link and the inverter at least partly form the maximum current inducing means.6. The power electronic device according to claim 5 , wherein the fault detecting means control the inverter to feed excessive energy to inverter load.7. ...

ANTAGONISTIC DR3 LIGANDS

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. 1. A method of treating an inflammatory disease comprising administering to a patient in need thereof an isolated monovalent antagonistic anti-DR3 antibody , the antibody comprising a heavy chain variable region comprising a heavy chain CDR1 , a heavy chain CDR2 , and a heavy chain CDR3 and a light chain variable region comprising a light chain CDR1 , a light chain CDR2 , and a light chain CDR3 , the heavy chain CDR1 comprising an amino acid sequence corresponding to Kabat residues 31-35 of SEQ ID NO:10; the heavy chain CDR2 comprising an amino acid sequence corresponding to Kabat residues 50-58 of SEQ ID NO:10; the heavy chain CDR3 comprising an amino acid sequence corresponding to Kabat residues 95-102 of SEQ ID NO:10; the light chain CDR1 comprising an amino acid sequence corresponding to Kabat residues 24-34 of SEQ ID NO:11; the light chain CDR2 comprising an amino acid sequence corresponding to Kabat residues 50-56 of SEQ ID NO:11; and the light chain CDR3 comprising an amino acid sequence corresponding to Kabat residues 89-97 of SEQ ID NO:11.2. The method of treating an inflammatory disease of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:10 claim 1 , and wherein the light chain variable region comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:11.3. The method of treating an inflammatory disease of claim 2 , wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:10 claim 2 , and wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:11.4. The method of treating an inflammatory disease of claim 1 , wherein the monovalent antibody is conjugated to a lipophilic moiety.5. The method of treating an inflammatory ...

Growth Hormones with Prolonged In-Vivo Efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy. 1. A growth hormone conjugate which comprises a growth hormone compound (GH) havinga) a single Cys mutation,b) an additional disulfide bridge, orc) a single Cys mutation and an additional disulfide bridge,wherein an albumin binding residue via a hydrophilic spacer is linked to said GH, ora pharmaceutically acceptable salt thereof.2. The conjugate of wherein the growth hormone conjugate has the formula (I):{'br': None, 'A-W—B-GH\u2003\u2003(I)'}whereinGH represents the growth hormone compound;B represents a hydrophilic spacer;W is a chemical group linking A and B; andA represent an albumin binding residue;and pharmaceutically acceptable salts thereof.3. The conjugate of wherein the hydrophilic spacer is linked toa) the N-terminal or Gln40 or Gln141 of the growth hormone compound orb) the sulphur residue of a single Cys mutation present in the growth hormone compound selected from the group consisting of T3C, P5C, S7C, D11C, H18C, Q29C, E30C, E33C, A34C, Y35C, K38C, E39C, Y42C, S43C, D47C, P48C, S55C, S57C, P59C, S62, E65C, Q69C, E88C, Q91C, S95C, A98C, N99C, S100C, L101C, V102C, Y103C, D107C, S108C, D112C, Q122C, G126C, E129C, D130C, G131C, P133C, T135C, G136C, T142C, D147C, N149C, D154C, A155C, L156C, R178C, E186C, G187C and G190C of SEQ ID NO: 1.4. The conjugate of claim 1 , wherein the GH has an additional disulfide bridge between at least one of the amino acid pairs in the positions selected from the group consisting of R16C/L117C claim 1 , A17C/E174C claim 1 , H21C/M170C claim 1 , D26C/V102C claim 1 , D26C/Y103C claim 1 , N47C/T50C claim 1 , Q49C/G161C claim 1 , F54C/Y143C claim 1 , F54C/S144C claim 1 ...

APPARATUS, METHOD, SYSTEM AND SOFTWARE PRODUCT FOR HAND SANITISATION

A method of implementing and using an apparatus () to achieve hand sanitisation by application of ozone. The apparatus has a disinfecting chamber () with at least one port () adapted for insertion of at least one hand into the disinfecting chamber (). A sensor () detects entry and/or exit of the hand () into the disinfecting chamber (). An ozone water output () of an ozone water supply () is arranged to deliver ozone water to the at least one hand () when inserted into the disinfecting chamber (). Control means () times start and stop of a discharge of ozone water from the at least one ozone water output () into the disinfecting chamber () when the at least one sensor () detects entry of the at least one hand () into the disinfecting chamber (). 129.-. (canceled)30. A method of hand sanitisation comprising the steps of:providing an apparatus for sanitisation of at least one hand by application of ozone water, the apparatus comprising, at least one port adapted for insertion of at least one hand into the disinfecting chamber,', 'at least one sensor adapted for detection of an entry and/or exit of the at least one hand into the disinfecting chamber,', 'at least one ozone water output of the disinfecting chamber comprises a first plurality of ozone water delivery openings arranged in a first pattern selected to deliver and spread a continuous flow of ozone water over the palm of the at least one hand inside the disinfection chamber, and a second plurality of ozone water delivery openings arranged in a second pattern selected to deliver and spread a continuous flow of ozone water over the back of the inserted at least one hand,, 'a disinfecting chamber having'}producing ozone water on demand by means of an ozone water supply that comprises an electrolytic ozone generator to obtain electrolytically produced ozone dissolved in water,sensing the introduction of the at least one hand through the at least one port, and starting a discharge of ozone water from the at least ...

Growth Hormones with Prolonged In-Vivo Efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

Growth Hormones with Prolonged In-Vivo Efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. 1. A growth hormone conjugate which comprises a growth hormone compound (GH) linked to an albumin binding residue via a hydrophilic spacer , or a pharmaceutically acceptable salt , solvate or prodrug thereof.2. The conjugate of wherein the growth hormone conjugate has the formula (I):{'br': None, 'A-W-B-GH\u2003\u2003(I)'}wherein:GH is a growth hormone compound,B is a hydrophilic spacer,W is a chemical group linking A and B, andA is an albumin binding residue.3. The conjugate of claim 1 , wherein GH is hGH (SEQ ID NO:1).4. The conjugate of wherein B has the formula{'br': None, 'sub': 1', '2', '3', '4, '-X-X-X-X-'}wherein{'sub': 1', '1', 'l1', '2', 'm1', '2', 'n1', 'm2', 'l2', '3', 'm3', 'n2, 'sup': 1', '2, 'Xis —W—[(CHR)—W]—{[(CH)E1]—[(CHR)—W]}—;'}{'sub': 2', 'l3', '4', 'm4', '2', 'n3', 'm5', 'l4', '5', 'm6', 'n4, 'sup': 3', '4, 'Xis —[(CHR)—W]—{[(CH)E2]—[(CHR)—W]}—;'}{'sub': 3', 'l5', '6', 'm7, 'sup': '5', 'Xis —[(CHR)—W]—;'}{'sub': 4', '2', 'l6, 'Xis F-D1-(CH)-D2-;'}l1, l2, l3, l4, l5 and l6 independently are selected from 0-16;m1, m3, m4, m6 and m7 independently are selected from 0-10;m2 and m5 independently are selected from 0-25;n1, n2, n3 and n4 independently are selected from 0-16;{'sub': 2', '2', '1-6, 'F is aryl, hetaryl, pyrrolidine-2,5-dione or a valence bond, wherein the aryl and hetaryl groups are optionally substituted with halogen, —CN, —OH, —C(O)OH, —C(O)NH, —S(O)OH or C-alkyl;'}{'sup': 1', '2', '3', '4', '5, 'sub': 2', '2', '2', '1-6, 'R, R, R, Rand Rindependently are selected from hydrogen, —C(O)OH, —C(O)NH, —S(O)OH, —S(O)OH, —NH—C(═NH)—NH, C-alkyl, aryl or hetaryl;'}wherein{'sub': 2', '2, 'the alkyl, aryl and hetaryl groups optionally are substituted with halogen, —C(O)OH, —C(O)NH, —S(O)OH, —S(O)OH, —CN or —OH;'}{'sup': 6', '7', '6', '7, 'sub': 1-6', '1 ...

Growth Hormones with Prolonged In-Vivo Efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy. 1. A growth hormone conjugate which comprises a growth hormone compound (GH) havinga) a single Cys mutation,b) an additional disulfide bridge, orc) a single Cys mutation and an additional disulfide bridge,wherein an albumin binding residue via a hydrophilic spacer is linked to said GH, ora pharmaceutically acceptable salt thereof.2. The conjugate of wherein the growth hormone conjugate has the formula (I):{'br': None, 'A-W-B-GH\u2003\u2003(I)'}whereinGH represents the growth hormone compound;B represents a hydrophilic spacer;W is a chemical group linking A and B; andA represent an albumin binding residue;and pharmaceutically acceptable salts thereof.3. The conjugate of wherein the hydrophilic spacer is linked toa) the N-terminal or Gln40 or Gln141 of the growth hormone compound orb) the sulphur residue of a single Cys mutation present in the growth hormone compound selected from the group consisting of T3C, P5C, S7C, D11C, H18C, Q29C, E30C, E33C, A34C, Y35C, K38C, E39C, Y42C, S43C, D47C, P48C, S55C, S57C, P59C, S62, E65C, Q69C, E88C, Q91C, S95C, A98C, N99C, S100C, L101C, V102C, Y103C, D107C, S108C, D112C, Q122C, G126C, E129C, D130C, G131C, P133C, T135C, G136C, T142C, D147C, N149C, D154C, A155C, L156C, R178C, E186C, G187C and G190C of SEQ ID NO: 1.4. The conjugate of claim 1 , wherein the GH has an additional disulfide bridge between at least one of the amino acid pairs in the positions selected from the group consisting of R16C/L117C claim 1 , A17C/E174C claim 1 , H21C/M170C claim 1 , D26C/V102C claim 1 , D26C/Y103C claim 1 , N47C/T50C claim 1 , Q49C/G161C claim 1 , F54C/Y143C claim 1 , F54C/S144C claim 1 ...

TWO-DIMENSIONAL AMORPHOUS CARBON COATING AND METHODS OF GROWING AND DIFFERENTIATING STEM CELLS

Described is a composite material composed of an atomically thin (single layer) amorphous carbon disposed on top of a substrate (metal, glass, oxides) and methods of growing and differentiating stem cells. 1. A two-dimensional (2D) amorphous carbon film , wherein the 2D amorphous carbon film has a crystallinity (C)≤0.8.2. The two-dimensional (2D) amorphous carbon film of claim 1 , wherein the 2D amorphous carbon film has a resistivity of 0.01 to 1000 Ω-cm claim 1 , inclusive.3. A two-dimensional (2D) amorphous carbon film claim 1 , wherein the 2D amorphous carbon film has a crystallinity (C)<1 and a sp/spbond ratio is 0.2 or less.4. An article comprising:a substrate; anda two-dimensional (2D) amorphous carbon film disposed on a surface of the substrate, wherein the 2D amorphous carbon film has a crystallinity (C)≤0.8.5. The article of claim 4 , wherein the substrate is selected from the group consisting catalytic metal claim 4 , non-catalytic metal claim 4 , glass claim 4 , plastic claim 4 , bioactive material claim 4 , tissue culture plate and an oxide of a material.6. The article of claim 4 , wherein an adhesion force between the surface of the substrate upon which the 2D amorphous carbon film is disposed and the 2D amorphous carbon film is ≥200 J/m2.7. A method of forming the article of claim 4 , the method comprising:decomposing a precursor gas to generate at least one decomposed species; andforming the 2D amorphous carbon film from the decomposed species on a surface of the substrate,wherein the precursor gas comprises a carbon-containing gas.8. The method of claim 7 , comprising:heating the substrate to a temperature of ≤500° C. prior to the forming.9. The method of claim 7 , wherein the 2D amorphous carbon film is formed as a continuous film over substantially the entire substrate surface.10. The method of claim 7 , comprising:separating the 2D amorphous carbon film from the surface of the substrate to obtain a free-standing 2D amorphous carbon film.11. The ...

AIR-COOLED MOTOR CONTROLLER FOR CONTROLLING AT LEAST ONE ELECTRIC MOTOR AND METHOD FOR CONTROLLING A FAN OF A CORRESPONDING MOTOR CONTROLLER

The present invention refers to an air-cooled motor controller for controlling electric motors, comprising a heat-sink and a variable fan for cooling passive and active components of the motor controller by means of an air stream generated by the fan. The invention is directed towards a fan control means and a coupled fan control method for controlling the speed of the fan of the motor controller in response to the losses in both passive and active devices inside the motor controller. 1. An air-cooled motor controller for controlling at least one electric motor , said motor controller comprising a heat sink and a variable-speed fan for cooling passive and active components of the motor controller by means of an air stream generated by the fan , wherein the first controller sets a base speed of the fan based on the characteristics of the active components attached to the heat sink, and wherein', 'the second controller is fed by the power loss of at least one passive component of the motor controller for adding an additional speed contribution to said base speed of the fan., 'the controller combines a first controller with a second controller for controlling the fan, wherein'}2. The air-cooled motor controller according to claim 1 , wherein the first controller is a PI-controller responding to the difference between a heat-sink-temperature reference (T) and a measured heat-sink temperature (T).3. The air-cooled motor controller according to claim 1 , wherein the second controller is a P-controller responding to the power loss of a passive component of the motor controller.4. The air-cooled motor controller according at least to claim 2 , wherein the heat-sink-temperature reference (T) for the first controller is a function of the ambient temperature of the motor controller.5. The air-cooled motor controller according to claim 4 , wherein the mathematical relation between the ambient temperature and the heat-sink-temperature reference (T) is determined according to ...

APPARATUS AND METHOD FOR CLEANING CONTAINERS FOR PRESSURIZED GAS

Apparatus () for cleaning the interior of a gas container () for pressurized gas; said apparatus comprising: —a rig () comprising container receiving means () for suspending said container; —an array () of elongate arms (′″), wherein said array () of elongate arms comprises: ii) an endoscope () comprising in its first end () image capturing means (); and ii) a blasting arm () comprising in its first end (′) a bias ling nozzle (); wherein said apparatus comprises means (′) for independently moving one or more of said elongate arms (′″), relative to said container receiving means (), in such a way that the first end (′″) of said one or more of said elongate arms can be inserted into the interior of a gas container (), when said gas container is suspended in said rig. 12. An apparatus for cleaning the interior of a gas container () for pressurized gas; said apparatus comprising:a rig, said rig comprising container receiving means for suspending said container; an array of elongate arms, each having a first end, and a second end;wherein said array of elongate arms comprising:ii) an endoscope comprising in its first end image capturing means for visual inspection of the interior of said container; andii) a blasting arm comprising in its first end a blasting nozzle for abrasive blasting the interior of the container;wherein said apparatus comprises means for independent moving one or more of said elongate arms of the array of elongate arms, relative to said container receiving means, in such a way that the first end of said one or more of said elongate arms of the array of elongate arms can be inserted into the interior of a gas container, when said gas container being suspended in said rig.2. An apparatus according to claim 1 , wherein said array of elongate arms further comprises an air blasting arm comprising in its first end an air nozzle for blowing compressed air into the interior of said container.3. An apparatus according to further comprising an air compressor ...

Liquid pharmaceutical composition of factor vii polypeptide

The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VIIa polypeptide, a buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and an active site stabilizing agent, which is selected from the group of: (S)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2′-dihydroxy-5′-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; (R)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2′-dihydroxy-5′-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; and a mixture of the (S)- and (R)-forms or pharmaceutically acceptable salts thereof. The invention further relates to said composition for treatment of a Factor VII-responsive bleeding disorder; methods for preparing the liquid composition and for stabilizing Factor VIIa in a liquid aqueous composition; an air-tight container containing the liquid, aqueous pharmaceutical composition and optionally an inert gas; and a method of treating a Factor VII-responsive bleeding disorder in a patent.

Protein Conjugates

The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products. 4. The conjugate according to claim 1 , wherein the sulfur atom's (—S—) are part of thioethers (—CH—S—CH—).5. The conjugate according to claim 3 , wherein U comprises or consists of a nitrogen atom.7. The conjugate according to claim 1 , wherein the conjugate has the structure:{'br': None, 'sub': 1', '2', '2, 'Protein-RR-S1-U[S2—NH—C(═O)—CH—S-Fc]'}whereinRR represents a reactive end radical,U represents a central unit,S1 and S2 represent individual spacers andFc is an Fc polypeptide.8. The conjugate according to claim 1 , wherein Proteinis a growth hormone.9. The conjugate according to claim 1 , wherein the conjugate has the structure:{'br': None, 'sub': 2', '2, 'GH-RR-S 1-U-[S2—NH—C(═O)—CH—S-Fc]'}whereinGH represents a growth hormone molecule,RR1 represents a reactive end radical,U represents a central unit,S1 and S2 represent individual spacers andFc is an Fc polypeptide.10. The conjugate according to claim 6 , wherein the hinge region of each Fc polypeptide includes a Cys residue.11. The conjugate according to claim 1 , wherein the sulfur atoms (—S—) are derived from protein cysteines claim 1 , such as selected from wild type Cys residues or from variant Cys residues.12. The conjugate according to claim 3 , wherein Proteinand S1 are linked via —S—CH—C(═O)—NH—.15. A method for preparation of a protein conjugate claim 3 , wherein Protein-SH claim 3 , Protein-SH and a thiol reactive linker are coupled together obtaining a protein conjugate of Formula II{'br': None, 'sub': 1', '2', '2', '2, 'Protein-S—CH—C(═O)—NH-Linker-NH—C(═O)—CH—S-Protein\u2003\u2003(Formula II)'} {'br': None, 'sup': 1', '2, 'sub': 2', '2, 'LG—CH—C(═O)—NH-Linker-NH—C(═O)—CH-LG,'}, 'wherein the thiol reactive linker has the structure{'sup': 1', '2, 'wherein LGhas a higher reactivity ...

Antagonistic DR3 Ligands

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Growth Hormones with Prolonged In-Vivo Efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

PRODUCT CONFIGURATION

Methods, computer systems and computer readable storage mediums for configuring a product based on a product model are provided. The product model has variables and rules. Each variable is associated with a set of values. The rules represent inter-dependencies among the variables and values. The variables and rules define a product configuration problem to be solved. A Decomposable And Or Graph, DAOG, is generated. The DAOG represents the product model. Subsequently, values for the variables of the product model are iteratively set based on the DAOG.

PROTON CONDUCTIVE TWO-DIMENSIONAL AMORPHOUS CARBON FILM FOR GAS MEMBRANE AND FUEL CELL APPLICATIONS

Described is a fuel cell comprising an electrode catalyst assembly, and a two-dimensional (2D) amorphous carbon, wherein the 2D amorphous carbon has a crystallinity (C)≤0.8. 1. A fuel cell comprising:an electrode catalyst assembly; anda two-dimensional (2D) amorphous carbon, wherein the 2D amorphous carbon has a crystallinity (C)≤0.8.2. The fuel cell of claim 1 , wherein the 2D amorphous carbon is a membrane.3. The fuel cell of claim 1 , wherein the 2D amorphous carbon is a film.4. The fuel cell of claim 1 , wherein the 2D amorphous carbon has a resistivity of 0.01 to 1000 Ω-cm claim 1 , inclusive.5. The fuel cell of claim 1 , further comprising:a proton exchange membrane.6. The fuel cell of claim 5 , wherein the 2D amorphous carbon is disposed between the electrode catalyst assembly and the proton exchange membrane.7. The fuel cell of claim 5 ,wherein the electrode catalyst assembly comprises multiple electrode catalyst assemblies,wherein the proton exchange membrane is disposed between the multiple electrode catalyst assemblies and the 2D amorphous carbon is disposed between each electrode catalyst assembly and the proton exchange membrane.8. The fuel cell of claim 5 ,wherein the electrode catalyst assembly comprises multiple electrode catalyst assemblies,wherein the proton exchange membrane comprises multiple proton exchange membranes,wherein the 2D amorphous carbon is disposed between the multiple proton exchange membranes, and the multiple proton exchange membranes are disposed between the multiple electrode catalyst assemblies.9. The fuel cell of claim 8 , wherein the proton exchange membrane is a fluoropolymer.10. The fuel cell of claim 9 , wherein the fluoropolymer is Nation®.11. A fuel cell comprising:an electrode catalyst assembly; and{'sup': 3', '2, 'a two-dimensional (2D) amorphous carbon, wherein the 2D amorphous carbon has a crystallinity (C)<1 and a sp/spbond ratio is 0.2 or less.'}12. The fuel cell of claim 11 , wherein the 2D amorphous carbon is a ...

VARIANT ANTIBODIES FOR SITE-SPECIFIC CONJUGATION

Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine. 1. A variant antibody of the IgG isotype , comprising an Fc region having a cysteine substitution at one of positions 271 , 337 , 340 , 341 , 343 , 402 , 413 , 415 , 419 , 439 , 440 , and 441 , the numbering of the positions being according to the EU index as in Kabat.2. A variant antibody according to claim 1 , wherein the cysteine substitution is at one of positions 337 claim 1 , 340 claim 1 , 341 claim 1 , and 343.3. A variant antibody according to claim 1 , wherein the cysteine substitution is at one of positions 413 and 415.4. A variant antibody according to claim 1 , wherein the cysteine substitution is at one of positions 439 claim 1 , 440 claim 1 , and 441.5. A variant antibody according to claim 1 , which is a human monoclonal antibody of the IgG1 isotype.7. An antibody-drug conjugate according to claim 6 , wherein drug D is a DNA alkylator claim 6 , a tubulysin claim 6 , an auristatin claim 6 , a pyrrolobenzodiazepine claim 6 , an enediyne claim 6 , or a maytansinoid compound.8. An antibody-drug conjugate according to claim 6 , wherein n is 1 and m is 1 or 2.9. An antibody-drug conjugate according to claim 6 , wherein variant antibody Ab is a human monoclonal antibody of the IgG1 isotype.11. An antibody-drug conjugate according to claim 10 , wherein drug D is a DNA alkylator claim 10 , a tubulysin claim 10 , an auristatin claim 10 , a pyrrolobenzodiazepine claim 10 , an enediyne claim 10 , or a maytansinoid compound.12. An antibody-drug conjugate according to claim 10 , wherein u is 1.13. An antibody-drug conjugate according to claim 10 , wherein antibody Ab is a human monoclonal antibody of the IgG1 isotype.14. A method of making an antibody-drug conjugate claim 1 , comprising reacting a variant antibody according to with a linker-drug compound wherein the linker has a cysteine-reactive functional ...

A dental implant analog

The present invention relates to a dental implant analog, an implant analog kit comprising the dental implant analog, the combination of a physical model of a set of a patient's teeth and the dental implant analog and a method of positioning a dental implant analog into a physical model of a set of a patient's teeth.

Anticuerpos variantes para conjugacion especifica de sitio.

Anticuerpos variantes que tienen sustituciones de cisteína en posiciones seleccionadas en la región Fc se pueden conjugar a través del grupo tiol de la cisteína sustituida.

Variant antibodies for site-specific conjugation

Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine.

Modulators of protein tyrosine phosphatases (ptpases)

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Dose setting device

A dose setting device for a delivery system has a piston rod ( 6, 9 ) which successively presses a piston ( 2 ) into a cylinder ampoule ( 1 ). Doses are set by rotating a second part ( 9 ) of the piston rod ( 6, 9 ) in relation to a first part ( 6 ). The two parts are connected by mating threads so that the total length of the piston rod ( 6, 9 ) is increased proportional to the angle of rotation, and a point ( 18 ) on the second part is moved away from a stop position fixed in relation to a housing ( 5 ) The set dose is delivered when the point ( 18 ) is moved back to the stop position. The first part ( 6 ) can be axially displaced but not rotated in the housing ( 5 ), and the second part ( 9 ) can both rotate and be axially displaced. The first part ( 6 ) is maintained in abutment with the piston ( 2 ) and the second part ( 9 ) is coupled to be rotated by a dose setting wheel ( 20 ). An injection push button ( 10 ) is movable between a projecting position and a pressed home position and has elements ( 13 ) acting on the second part ( 9 ) to press this part to its stop position.

Conjugated proteins with prolonged in vivo efficacy

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Growth hormones with prolonged in-vivo efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.

Growth hormones with prolonged in-vivo efficacy

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

Conjugated proteins with prolonged in vivo efficacy

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Growth hormones with prolonged in-vivo efficacy

The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.

New amide derivatives and pharmaceutical use thereof

The use of substituted amides for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11 βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11 βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Single chain fc type iii interferons and methods of using same

The present invention relates to single chain Fc Type III Interferon fusion proteins and methods of using same. The single chain Fc Type III Interferon fusion proteins comprise at least one Type III Interferon, two Fc regions and at least one linker, can be produced in a variety of single chain configurations, and are effector function minus or have a substantially reduced effector function.

Conjugated proteins with prolonged in vivo efficacy

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

Syringe with tiltable nut for quick piston disengagement

In a syringe dosing mechanism a threaded spindle (1) and a nut (3) cooperates so that relative rotation thereof moves the nut (3) along the spindle (1). The nut (3) has two intersecting bores (12, 15). The first bore (15) has an inner thread (7) matching the outer thread (2) of the spindle (1) and the second bore (12) is smooth and fits slidingly over the spindle (1). The nut (3) is tiltable between a first and a second position. In the first position the threaded bore (15) is coaxial with the spindle (1) and in the second position the smooth bore (12) is coaxial with the spindle (1). The nut (3) is at a first side hinged to a piston rod (6)so that exertion of a force by the nut (3) on the piston rod (6) in a direction (10) by which an injection is performed will tilt said nut (3) into its first position. A piston withdrawal member acts at a second side of said nut diametrically opposite said first side so that the nut (3) is tilted to its second position when the withdrawal member applies a force (13) to said nut (3).

Modulators of protein tyrosine phosphatases (PTPases)

The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, wherein A, R 1 , R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Somatostatin agonists and antagonists

The present invention relates to compounds, compositions containing them, and their use for treating medical disorders related to binding to human somatostatin receptor subtypes.

Dose setting device

By a dose setting device for a delivery system wherein a piston rod (6, 9) succesively presses a piston (2) into a cylinder ampoule (1) a dose is se t by rotating a second part (9) of the piston rod (6, 9) in relation to a first part (6) which parts are connected by mating threads so that the total length of the piston rod (6, 9) is increased proportionally with the rotation and a point (18) on the second part is moved away from a stop position fixedin relation to a housing (5). The set dose is delivered when said point (18) is moved back to the sto p position. The first part (6) can be axially displaced but not rotated in the housing (5), and the second part (9) can be as well rotated as axially displaced. Th e first part (6) is maintained in abutment with the piston (2) and the second part ( 9) is coupled to be rotated by a dose setting wheel (20). An injection push button (10) is movable between a projecting position and a pressed home position an d has elements (13) acting on the second part (9) to press this part to its st op position.

Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors

The use of substituted amides of structure (I) for modulating the activity of 11 .beta.-hydroxysteroid dehydrogenase type 1 (11 .beta.HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11 .beta.HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Apparatus, method and software product for hand sanitisation by application of ozonated water

An apparatus (1a,1b,13,25), and a method of implementing and using the apparatus, serve for hand sanitisation by application of ozone. The apparatus comprises a disinfecting chamber (3,3',110) having at least one port (2) adapted for insertion of at least one hand into the disinfecting chamber 10 (3,110). A sensor (4) detects entry and/or exit of the hand (26) into the disinfecting chamber (3,110). An ozone water output (7,130) of an ozone water supply (8) is arranged to deliver ozone water to the at least one hand (26) when inserted into the disinfecting chamber (3,110). Control means 15 (6) times start and stop of a discharge of ozone water from the at least one ozone water output (7,130) into the disinfecting chamber (3,110) when the at least one sensor (4) detects entry of the at least one hand (26) into the disinfecting chamber (3,110).

New Heterocyclic Compounds

Conjugated proteins with prolonged in vivo efficacy

The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.

USE OF D-TAGATOSA COMOSINERGIZADOR AND INTENSIFIER OF TASTE.

Uso de D-tagatosa a una concentración entre el 0, 01% y el 5, 0% por peso/volumen, para sinergizar el efecto de un edulcorante intenso o una mezcla de edulcorantes intensos. Use of D-tagatose at a concentration between 0.01% and 5.0% by weight / volume, to synergize the effect of an intense sweetener or a mixture of intense sweeteners.

ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TAURIN DERIVATIVES.

Novel heterocyclic compounds

A compound of formula (I) in which Z is selected from (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), and (k). The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Fused 1,2,4-triazoles and pharmaceutical uses thereof

The use of fused 1,2,4-triazoles for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Support to be mounted on a ski

A support having two ski bindings, arranged side by side, to be mounted on a ski. The lower part of the support (1) is moulded in such a way in its lower region that the support (1) can be tightened, in the same way as a ski boot, on the ski binding (5, 6) of a ski (4), with the ski bindings (2, 3) on the upper side of the support lying symmetrically relative to the ski in a known manner. <IMAGE>

Method for detecting earth fault conditions in a motor controller

Verfahren zur im laufenden Betrieb erfolgenden Überprüfung, ob ein Erdschluss vorliegt, um dadurch eine Motorsteuerung zu schützen, welche eine auf einer Highside-Seite und eine auf einer Low-side-Seite liegende Gleichstromleitung aufweist, welche auf einer Highside-Seite und auf einer Lowside-Seite liegende Schaltelemente aufweist, wobei die auf der Highside-Seite und die auf der Low-side-Seite liegenden Schaltelemente im Betrieb jeweils mit entsprechenden auf der Highside-Seite und auf der Lowside-Seite liegenden Gleichstromleitungsbussen verbunden sind, wobei das Verfahren folgende Schritte aufweist: – Erzeugung eines Fehlersignals, wobei das Fehlersignal anormale Betriebszustände der Motorsteuerung anzeigt, – Erzeugung zumindest eines Testvektors durch Einschalten zumindest eines der Schaltelemente als Antwort auf das Fehlersignal und – während zumindest ein Schaltelement angeschaltet ist, Messung der Größe eines Stroms, der in der Gleichstromleitung fließt, die im Betrieb mit dem leitenden Schaltelement/den leitenden Schaltelementen verbunden ist, um einen Erdschlussfehler zu detektieren, – wobei alle Schaltelemente ausgeschaltet werden, bevor zumindest ein Schaltelement eingeschaltet wird. A method of checking, on an ongoing basis, whether there is a ground fault, thereby protecting a motor controller having a high side and a low side side direct current line running on a high side and on a low side Side lying switching elements, wherein the lying on the high side and the low-side side switching elements are connected in operation with respective lying on the high side and on the lowside side DC bus buses, the method following steps generating at least one test vector by turning on at least one of the switching elements in response to the error signal, and while at least one switching element is turned on, measuring the magnitude of a current that is in the DC line flows in Be drive is connected to the conductive switching element (s) to detect a ground fault, ...

Novel heterocyclic compounds

A compound of formula (I). The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Somatostatin agonists and antagonists

The present invention relates to somatostatin ligands (Ia) or (Ib) which are useful for treating medical disorders related to binding to human somatostatin receptor subtypes, wherein X is =S, =O, =NH, =NCOPh or =N(CN), A is aryl optionally substituted with halogen, amino, hydroxy, nitro, C1-6-alkyl, C1-6-alkoxy or aryl, B is aryl optionally substituted with halogen, amino, hydroxy, C1-6-alkyl, C1-6-alkoxy or aryl, D is aryl, amino, optionally substituted with halogen, amino, hydroxy, C1-6-alkyl, C1-6-alkoxy or aryl, or a pharmaceutically acceptable salt thereof.

Modulators of molecules with phosphotyrosine recognition units

The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in in vitro systems, microorganisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of formula (I) ##STR1## wherein (L) n , Ar 1 , R 1 and A are as defined in the application.

Apparatus, method and software product for hand sanitisation by application of ozonated water

An apparatus (1a,1b,13,25), and a method of implementing and using the apparatus, serve for hand sanitisation by application of ozone. The apparatus comprises a disinfecting chamber (3,3',110) having at least one port (2) adapted for insertion of at least one hand into the disinfecting chamber 10 (3,110). A sensor (4) detects entry and/or exit of the hand (26) into the disinfecting chamber (3,110). An ozone water output (7,130) of an ozone water supply (8) is arranged to deliver ozone water to the at least one hand (26) when inserted into the disinfecting chamber (3,110). Control means 15 (6) times start and stop of a discharge of ozone water from the at least one ozone water output (7,130) into the disinfecting chamber (3,110) when the at least one sensor (4) detects entry of the at least one hand (26) into the disinfecting chamber (3,110).

Compound, processes for preparing a compound, treating neurogenic inflammation and rheumatoid arthritis, pharmaceutical composition, pharmaceutical compositions suitable for treating neurogenic inflammation, for treating neuropathy, for treating rheumatoid arthritis, for reducing blood glucose, for inhibiting cgrp activity, for treating migraine, to treat itching, and use of a compound

"COMPOSTO, PROCESSOS PARA PREPARAR UM COMPOSTO, TRATAR INFLAMAçãO NEUROGêNICA E ARTRITE REUMATóIDE, COMPOSIçãO FARMACêUTICA, COMPOSIçõES FARMACêUTICAS ADEQUADAS PARA TRATAR INFLAMAçãO NEUROGêNICA, PARA TRATAR NEUROPATIA, PARA TRATAR ARTRITE REUMATóIDE, PARA REDUZIR GLICOSE DO SANGUE, PARA INIBIR A ATIVIDADE DO CGRP, PARA TRATAR ENXAQUECA, PARA TRATAR COCEIRA, E, USO DE UM COMPOSTO". A presente invenção refere-se a novos ácidos carboxíliocos azaeterocíclicos N-substituídos, de fórmula geral (I): em que X, Y, Z, R^ 1^, R^ 2^ e r são como definidos na pate detalhada da descrição, ou seus sais, a processos para sua preparação, a composições contendo-os e a seu uso para o tratamento clínico de condições dolorosas, hiperalgésicas e/ou inflamatórias, em que as fibras-C representam um papel patofisiológico, pela eliciação da dor ou inflamação neurogênica, bem como seu uso para tratamento de indicações causadas por ou relacionadas com a secreção e circulação de insulina antagonizando peptídeos.

A method and an apparatus for analyzing a state based system model

The invention relates to a method of analyzing a state based system model comprising a set of machines (M1, .., Mn), said machines each comprising at least one possible state (pS1Mi, .., pSkMi), each machine being in one of its comprised states at any given time, the dynamic behavior of said machines (M1, .., Mn) being defined by predefined transitions between said states of each machine (M1, .., Mn) and dependencies (D) between said machines (M1, .., Mn). One of many important advantages of the invention is that many analyses of real-life state based system models can be performed without evaluation of a considerable amount of machines in the system model.

Pharmaceutical use of substituted amides

N-substituted azaheterocyclic carboxylic acids and esters thereof, pharmaceutical compositions containing them, process for their preparation and their use for treatment of neurogenic inflammations

Heterocyclic compounds for use in the treatment of neurogenic inflammation

A compound of formula (I). The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

Adjustable nut

Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines

The use of substituted pyrazolo[1,5- a ]pyrimidines for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions are described. Also a novel class of substituted pyrazolo[1,5- a ]pyrimidines their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Two-dimensional amorphous carbon film and method for growing and differentiating stem cell

【課題】基材（金属、ガラス、酸化物）の頂部に配置された原子的に薄い（単層）アモルファス炭素から構成される複合材料及び幹細胞の成長及び分化方法の提供。【解決手段】上記課題は、二次元（２Ｄ）アモルファス炭素フィルムであって、前記２Ｄアモルファス炭素が≦０．８の結晶化度（Ｃ）を有する二次元（２Ｄ）アモルファス炭素フィルムによって解決される。【選択図】なし

DNS SEQUENCE.

A DNA sequence containing a ribosome binding site with a SD sequence AGGA and a start codon ATG, comprising a nucleotide sequence having the formula Y1 . . . YmZVAGGA X1, X2 . . . XnATG wherein Y1 . . . Ym represents a promoter with one or more restriction enzyme sites, m being an integer corresponding to the number of base pairs in the promoter, each X, Y, Z and V is A, T, C or G; n is 9 to 13, and the sequence X1 . . . Xn cannot contain a start codon.

A method and an apparatus for analyzing a state based system model

The invention relates to a method of analyzing a state based system model comprising a set of machines (M1, .., Mn), said machines each comprising at least one possible state (pS1Mi, .., pSkMi), each machine being in one of its comprised states at any given time, the dynamic behavior of said machines (M1, .., Mn) being defined by predefined transitions between said states of each machine (M1, .., Mn) and dependencies (D) between said machines (M1, .., Mn). One of many important advantages of the invention is that many analyses of real-life state based system models can be performed without evaluation of a considerable amount of machines in the system model.

Ammonia cracking

A process for generating power using a gas turbine, comprising the steps of: (i) vaporising and pre-heating liquid ammonia to produce pre-heated ammonia gas; (ii) introducing the pre-heated ammonia gas into an ammonia-cracking device suitable for converting ammonia gas into a mixture of hydrogen and nitrogen; (iii) converting the pre-heated ammonia gas into a mixture of hydrogen and nitrogen in the device; (iv) cooling the mixture of hydrogen and nitrogen to give a cooled hydrogen and nitrogen mixture; (v) introducing the cooled hydrogen and nitrogen mixture into a gas turbine; and (vi) combusting the cooled hydrogen and nitrogen mixture in the gas turbine to generate power.

Novel heterocyclic compounds

Modulators of protein tyrosine phosphatases (PTPases)

The present invention provides novel compounds of Formula 1 or Formula 2 and compositions thereof, methods of their use, and methods of their manufacture, wherein X, Y, Z, W, R 1 , R 2 and R 3 are defined more fully in the description. These compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and a number of other diseases.

Novel heterocyclic compounds

Dose setting device

Novel heterocyclic compounds

NEW HETEROCYCLIC COMPOUNDS

Pharmaceutical use of substituted amides

The use of substituted amides for modulating the activity of 11.beta.-hydroxysteroid dehydrogenase type 1 (11.beta.HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11.beta.HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

Pharmaceutical use of substituted amides

Method for manufacturing a hydrogen and nitrogen containing gas mixture

The present invention relates to a method for manufacturing a hydrogen- and nitrogen containing gas mixture, where a mixture of steam and a carbon containing gas is fed to the retentate side of at least one hydrogen transpo rt membrane syngas and sweep gas generator where said gas and steam are convert ed to synthesis gas. A part of the hydrogen in said synthesis gas is transporte d through the membrane to the permeate side in said generator where it reacts with oxygen in an air stream fed to said permeate side to generate heat and a nitrogen and steam containing gas. The synthesis gas is further fed to the retentate side of a downstream hydrogen transport membrane unit or a hydroge n transport membrane reactor where a major part of the hydrogen in said synthesis gas, and if a reactor is used, a major part of additional hydrogen generated at the retentate side in said reactor is transported through said downstream membrane and picked up by said nitrogen containing gas to form a hydrogen- and nitrogen containing gas mixture, Furthermore, the invention relates to a method for performing a catalytic or non-catalytic process wherein the hydrogen- and nitrogen containing gas mixture manufactured by th e method according to claims 1-6 is applied as one of the reactants in said process.

A dental implant analog

The present invention relates to a dental implant analog, an implant analog kit comprising the dental implant analog, the combination of a physical model of a set of a patient's teeth and the dental implant analog and a method of positioning a dental implant analog into a physical model of a set of a patient's teeth.

Apparatus and method for absorbing co2 from flue gas

Fueling gas turbines with cracked ammonia

A process for generating power using a gas turbine, comprising the steps of: (i) vaporising and pre-heating liquid ammonia to produce pre-heated ammonia gas; (ii) introducing the pre-heated ammonia gas into an ammonia-cracking device suitable for converting ammonia gas into a mixture of hydrogen and nitrogen; (iii) converting the pre-heated ammonia gas into a mixture of hydrogen and nitrogen in the device; (iv) cooling the mixture of hydrogen and nitrogen to give a cooled hydrogen and nitrogen mixture; (v) introducing the cooled hydrogen and nitrogen mixture into a gas turbine; and (vi) combusting the cooled hydrogen and nitrogen mixture in the gas turbine to generate power.

dose setting

THE DEOXY GENERATION OF AN OIL PRODUCT WITH A LACCASE

Syringe

"SERINGA". Em um mecanismo dosador de seringa, um fuso rosqueado (1) e uma porca (3) cooperam de modo que a sua rotação relativa desloca a porca (3) ao longo do fuso (1). A porca (3) tem dois furos (12, 15) que se interceptam. O primeiro furo (15) tem um rosqueamento interno (7) que se conjuga com o rosqueamento externo (2) do fuso (1) e o segundo furo (12) é liso e se encaixa deslizantemente sobre o fuso (10. A porca (3) é basculável entre uma primeira e uma segunda posições. Na primeira posição, o furo rosqueado (15) é coaxial com o fuso (1) e, na segunda posição, o furo liso (12) é coaxial com o fuso (1). A porca (3) é articulada em um primeiro lado em uma haste de êmbolo (6) de modo que ao se ao se exercer uma força pela porca (3) sobre a haste de êmbolo (6) em um sentido (10) pelo qual é aplicada uma injeção, vai-se bascular a dita porca (3) para a sua primeira posição. Um componente de retirada de êmbolo age em um segundo lado da dita porca diametralmente oposto ao dito primeiro lado de modo que a porca (3) é basculada para sua segunda posição quando o componente de retirada aplica uma força (13) à dita porca (3).

The combination of a physical model of a set of a patient's teeth and an elongated implant analog, and a method of making a physical model of a set of teeth

Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy

Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

An apparatus for flushing peripheral organs in humans or animals